No Data
Relmada Jumps as Jefferies Upgrades on a Potential Turnaround Story
Jefferies Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $13
Jefferies analyst Andrew Tsai initiates coverage on $Relmada Therapeutics(RLMD.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 55
Relmada Therapeutics Analyst Ratings
Express News | Relmada Therapeutics Inc : Jefferies Raises Target Price to $13 From $3.5
Express News | Relmada Therapeutics Inc : Jefferies Raises to Buy From Hold
Sergio Traversa Bought 57% More Shares In Relmada Therapeutics